medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 2

<< Back Next >>

Ann Hepatol 2011; 10 (2)

The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis

Yi Z, Jie YW, Nan Z

Language: English
References: 20
Page: 165-173
PDF size: 128.86 Kb.


ABSTRACT

Objectives. To assess the efficacy of anti-viral therapy on hepatitis B virus associated glomerulonephritis (HBV-GN). Design, setting, participants, & measurements. We searched PubMed, Embase and Cochrane Library for prospective controlled trials which assessed the efficacy of anti-viral therapy on HBV-GN in adult or pediatric patients between January, 1970 and October, 2010. Results were summarized using fixedeffects model because of an absence of heterogeneity among the studies (I2 = 0%). Results. Six trials with a total of 159 patients were included; among them five trials were specified as hepatitis B virus-associated membranous glomerulonephritis (HBV-MN). In adult patients, the incidence of proteinuria remission, not only total remission (complete remission CR + partial remission PR) (2.97 to 109.93, P = 0.002) but also CR (1.18 to 16.11, P = 0.03), significantly increased in the anti-viral treatment. In pediatric patients, only the incidence of total remission (1.77 to 17.75, P = 0.003) was increased significantly; the incidence of CR was not pooled with clinical and statistical heterogeneity (I2 = 81.5%, P = 0.004).Combine the data from adult and pediatric patients with HBV-MN, the same results were found. All the results of proteinuria remission kept with virologic response (VR), including HBeAg conversion (5.68 to 40.04, P ‹ 0.00001) and reduction of HBV-DNA (5.60 to 463.16, P = 0.0005). Conclusions. Antiviral therapy including IFN and lamivudine is effective on remission of proteinuria, HBeAg clearance, and HBV-DNA reduction.


REFERENCES

  1. Bhimma R, Coovadia HM, Adhikari M: Hepatitis B virus-associated nephropathy in black South African children. Pediatr Nephrol 1998; 12: 479-84.

  2. Combes B, Stastny P, Shorey J, Eigenbrodt EH, Barrera A, Hull AR, Carter NW. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 1971; ii: 234-7.

  3. Gocke DJ, Hsu K, Morgan C, Bombardien S, Locksmith M, Christian CL: Association between polyarteritis and Australia antigen. Lancet 1970; ii: 1149-56.

  4. Levy Y, Gorevic PD, Kassab HJ, Zucker-Franklin D, Franklin EC. Association between hepatitis B virus and essential mixed cyroglobulinemia. N Engl J Med 1977; 296: 1501-8.

  5. Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol 2004; 24: 198-211.

  6. Johnson RJ, Couser W. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37: 663–76.

  7. Walters S, Levin M. Infectious diseases and the kidney. In: Barratt TM, Avner ED, Harmon WE (ed.). Pediatric Nephrology. 4th Ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999, p. 1088-90.

  8. Appel GB, Radhakrishnan J, D’Agati V. Secondary glomerular disease. In: Brenner BM (ed.). The Kidney. 6th Ed. Philadelphia, PA: WB Saunders; 2000, p. 1411.

  9. Khan KS, Daya S, Jadad AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996; 156: 661-6.

  10. Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney International 1995; 47: 225-30.

  11. Bhimma R, Kramvis A, Charles KM. Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 2002; 17: 393-9.

  12. Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney International 2005; 68: 1750-8.

  13. Yang Q, Zhuang JQ, Lin RX, et al. Clinicopathological Features and Treatment of Hepatitis B Virus Associated Membranous Nephropathy in Children. Zhongguo Zhongxiyi Jiehe Shenbing Zazhi 2003; 54: 706-8.

  14. Panomsak S, Lewsuwan S, Eiam-Ong S, Kanjanabuch T. Hepatitis- B virus-associated nephropathies in adults: a clinical study in Thailand. J Med Assoc Thai 2006; 89(Suppl. 2): S151-S156.

  15. Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324: 1457-63.

  16. Hossein K, Saeed T. Hepatitis B virus-associated Nephropathy: An International Data Analysis. IJKD 2010; 4: 101-5.

  17. Lai MY, Yang WC, Lee SD,et al. Long-term lamivudine therapy is not reasonable for HBV-associated nephropathy. Advance Access publication.2005.doi:10.1093/ndt/ gfk001.

  18. Mesquita M, Lasser L, Langlet P. Long-term (7-year) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis. Clin Nephrol 2008; 70: 69-71.

  19. Ohtake T, Kobayashi S. Hepatitis B virus-related membranous nephropathy treated with entecavir. Nephrology 2010; 15: 266-7.

  20. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleotide- naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.




2020     |     www.medigraphic.com